The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging
Advanced Science · 2026
DOI: 10.1002/advs.202522550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xiaokun Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Research, Investigation and Evaluation…. Hauptthemen laut MEDLINE: Basigin, Positron Emission Tomography Computed Tomography, Neoplasms, Gallium Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Research Ward Excellence Program, Scientific Research Foundation of Peking University Cancer Hospital, National Key R&D Program of China.
Abstract (Originalsprache)
Extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) is highly expressed in multiple malignancies and represents a potential therapeutic target. Monitoring CD147 expression noninvasively may facilitate tumor detection and guide therapeutic strategies. We developed a novel peptide‐based PET probe, [ 68 Ga]Ga‐DOTA‐AP9, and validated its pharmacokinetics and specificity in preclinical and translational uEXPLORER total‐body PET/CT studies. In preclinical models, [ 68 Ga]Ga‐DOTA‐AP9 showed high binding affinity and specific uptake in CD147‐positive A375 tumors. Encouraged by the favorable tumor‐to‐background contrast and safety profile observed in animals, [ 68 Ga]Ga‐DOTA‐AP9 total‐body PET/CT imaging was performed in eleven participants with diverse cancer types and varying CD147 expression levels. Among the eleven participants, tumor lesions showed a maximum SUV max of 10.1 at 30 min p.i., and uptake correlated strongly with CD147 (r = 0.7981, P < 0.001), MCT1 (r = 0.8555, P < 0.001), and Ki67 (r = 0.8036, P < 0.001), but not GLUT1 ( P = 0.0668). Notably, [ 68 Ga]Ga‐DOTA‐AP9 uptake more accurately reflected CD147 expression than [ 18 F]F‐FDG, with divergent uptake patterns in some lesions. These findings support that [ 68 Ga]Ga‐DOTA‐AP9 enables sensitive, noninvasive detection and quantitative assessment of CD147‐positive tumors in vivo, provides complementary diagnostic information to [ 18 F]F‐FDG PET, and holds significant potential for patient stratification, treatment selection, therapeutic response monitoring, and guiding precision oncology strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory For Research and Evaluat…
- Beijing Key Laboratory of Research, Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Orthopeadics, Guizhou Provincial People's Hospital, Guiyang, China.
ORCID-Profile: Zhi Yang
Förderung
- Beijing Research Ward Excellence Program
- Scientific Research Foundation of Peking University Cancer Hospital
- National Key R&D Program of China
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Peking University Medicine Sailing Program for Young Scholars' Scientific & Technological Innovation and the Fundamental Research Funds for the Central Univers…
- Youth Beijing Scholar 2024
- Guizhou Provincial Science and Technology Department Basic Project
Zitieren
APA
Ma, X., Guo, R., Niu, D., Song, Y., Zhang, Z., Meng, X., Mao, L., Huang, H., Zhu, H., Yang, Z., & Liu, T. (2026). The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging. Advanced Science. https://doi.org/10.1002/advs.202522550
Vancouver
Ma X, Guo R, Niu D, Song Y, Zhang Z, Meng X, et al. The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging. Advanced Science. 2026. doi:10.1002/advs.202522550
BibTeX
@article{Ma2026,
author = {Ma, Xiaokun and Guo, Rui and Niu, Dongfeng and Song, Yufei and Zhang, Zhenyao and Meng, Xiangxi and Mao, Lili and Huang, Haifeng and Zhu, Hua and Yang, Zhi and Liu, Teli},
title = {The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202522550}
}
EUVIMED